Glioblastoma multifome is the most common and most aggressive primary brain tumor with no current curative therapy. We found expression of the bZip transcription factor ATF5 in all 29 human glioblastomas and eight human and rat glioma cell lines assessed. ATF5 is not detectably expressed by mature brain neurons and astrocytes, but is expressed by reactive astrocytes. Interference with ATF5 function or expression in all glioma cell lines tested causes marked apoptotic cell death. In contrast, such manipulations do not affect survival of ATF5-expressing cultured astrocytes or of several other cell types that express this protein. In a proof-of-principle experiment, retroviral delivery of a function-blocking mutant form of ATF5 into a rat glioma model evokes death of the infected tumor cells, but not of infected brain cells outside the tumors. The widespread expression of ATF5 in glioblastomas and the selective effect of interference with ATF5 function/expression on their survival suggest that ATF5 may be an attractive target for therapeutic intervention in such tumors.
Introduction
Malignant astrocytic tumors occur in the human population at a frequency of 7 per 100 000 per year (Rasheed et al., 1999; Maher et al., 2001) , making them the most common form of primary brain tumor. There is currently no effective curative therapy for patients with WHO classification Grade IV glioblastomas (also designated as glioblastoma multiforme (GBM)) and the average survival time from diagnosis is approximately 9-11 months (Kleihues et al., 1993; McLendon et al., 1998) .
Findings that neural progenitor/stem cells may be experimentally transformed into glioblastomas has supported the possibility that such tumors may arise from self-renewing progenitors that have lost the capacity for appropriate regulation of proliferation and survival (Dai and Holland, 2001) . Indeed, GBMs are often associated with disregulation of pathways that control growth and survival, including those involving p53, Rb, PTEN and growth factor receptors (reviewed by Collins (2004) ). Additional novel regulatory genes may also contribute to blocking GBM cells from undergoing full differentiation and maintaining them in a state of uncontrolled growth.
We have recently reported (Angelastro et al., 2003 ) that neural progenitor/stem cells in the developing brain express high levels of activating transcription factor 5 (ATF5; also referred to as ATFx), a member of the ATF/CREB family of bZip proteins (Jensen and Chiu, 1991; Nishizawa and Nagata, 1992; Pati et al., 1999; Hansen et al., 2002; Persengiev et al., 2002; Angelastro et al., 2003) . Cells in the developing nervous system that expressed ATF5 included neural stem cells positive for CD133, a marker recently shown to be expressed by tumor-initiating cells in glioblastomas and other brain tumors (Singh et al., 2004) . This contrasts with fully differentiated neurons, astrocytes and oligodendrocytes that do not show detectable expression of ATF5 in vivo (Angelastro et al., 2003 Mason et al., 2005) . Moreover, our studies revealed that ATF5 must be downregulated to permit neural progenitor cells to differentiate into neurons and glia. Thus, constitutive expression of exogenous ATF5 maintains neural progenitor cells in a proliferative state both in vitro and in vivo, and represses their differentiation in the presence of extracellular signals such as NGF, NT3 and CNTF that otherwise promote differentiation and downregulation of endogenous ATF5. By contrast, loss of ATF5 function or expression achieved with a dominantnegative (d/n) form of ATF5 or with a small interfering RNA (siRNA), respectively, accelerates the differentiation of neural progenitors into nondividing neurons and glia (Angelastro et al., 2003 Mason et al., 2005) .
Owing to ATF5's expression in neural progenitor/ stem cells, but not in mature astrocytes, and because of its capacity to maintain neuroprogenitor cells in a nondifferentiated, proliferating state, we questioned whether this protein might be expressed by glioblastoma cells. Also, if this were the case, we further questioned what the effect would be of inhibiting its expression or function in these cells. We report here that GBMs excised from human patients express ATF5 and that this protein is also expressed by human and rat glioma cell lines. Moreover, interference with ATF5 function or expression causes death of glioma cell lines both in culture and in an in vivo rat model. In contrast, the apoptotic response of glioma cells to ATF5 loss-offunction appears to be selective in that interference with ATF5 function does not affect survival of nonneoplastic proliferating brain cells such as activated glia.
Results

Human glioblastomas express nuclear ATF5
In rodent brains, proliferative neural progenitor cells express high levels of nuclear ATF5, whereas mature neurons and glia express little or no detectable levels of this protein (Angelastro et al., 2003 Mason et al., 2005) . We therefore assessed whether ATF5 might be expressed in highly proliferative glial tumors. A series of 29 surgically resected human GBM tumors (WHO Grade IV) were immunostained with ATF5 antiserum (Kleihues et al., 1993; McLendon et al., 1998) . All stained materials were examined by a neuropathologist (PDC) to verify the GBM diagnosis and to identify the stained cells. Positive specific nuclear staining was seen in the majority of glioma cells within all 29 tumors (Figure 1 ). Tumor cells were identified on the basis of cytologic atypia. Staining for the proliferation marker Ki67 also revealed a high density of proliferating cells within the tumor mass, consistent with the GBM diagnosis ( Figure 1c) .
Both within the tumors and in the overlying cortex, ATF5 staining was also seen in some cells with relatively round nuclei (Figure 1b, insert) . Some of these cells likely represent non-neoplastic/reactive glia. Staining was also present in some endothelial cells in regions of microvascular proliferation (not shown). In contrast, there was little or no staining of neurons within the tumors or in the surrounding tissue (Figure 1g ).
We also examined ATF5 expression by six wellcharacterized human and two rat glioma cell lines. As subsequent experiments assessed transfected cells, we transfected the cultures with an eGFP expression vector and examined both transfected and nontransfected cells. Each yielded similar results (Figure 2 and data not shown). All eight lines expressed nuclear ATF5 with 60-100% of the cells showing positive staining. Western blotting confirmed the presence of ATF5 protein in these lines as a single 22 kDa band (Figure 2 and data not shown). In contrast to the glioma lines, cultured normal non-neoplastic rat astrocytes isolated from neonatal rats, in the first or second passage, as in vivo, showed little or no ATF5 expression as assessed by immunostaining and Western immunoblotting (Figure 2a) . However, 60% of the cultured astrocytes expressed the ATF5 protein after >3 passages in vitro (Figure 2b) .
Interfering with the function or expression of ATF5 promotes apoptosis of glioma cells, but not activated astrocytes, in vitro We have observed that interfering with the expression or function of ATF5 in neural progenitor cells causes them to exit the cell cycle and to undergo accelerated differentiation (Angelastro et al., 2003 . We therefore next determined whether glioma cells respond similarly. To interfere with function, we transfected the glioma lines with a d/n ATF5 construct (eGFP-NTAzip-ATF5) (Angelastro et al., 2003 . Surprisingly, all seven lines tested responded to the d/n construct by showing high levels of death compared with cells transfected with a control construct expressing eGFP (Figures 3 and 4a) . By 5 days, 25-40% of the cells transfected with the d/n construct exhibited condensed chromatin indicative of apoptotic death (as compared with 2-8% of such cells transfected with the control construct). There was also a significant increased amount of floating cellular debris in the cultures transfected with d/n construct, suggesting that the level of cell death was even higher than measured. To confirm that death was apoptotic and to determine whether it was caspase-dependent, C6 cells were transfected with d/n ATF5 in the presence and absence of the general caspase inhibitor BAF (Deshmukh et al., 1996) . This resulted in a four-fold reduction in cell death (Figure 3m ).
To corroborate our findings with NTAzip-ATF5 and to rule out possible nonspecific actions of d/n ATF5, we also employed an siRNA oligoduplex that selectively downregulates ATF5 expression (Angelastro et al., 2003) . Compared with a control construct, the ATF5 siRNA promoted death of all four human glioma lines tested ( Figure 4b ). We also used a construct that expresses a short hairpin ATF5 siRNA driven by a U6 promoter and that reduced by 80% the proportion of transfected cells (as compared with cells transfected with a control construct) that were positive for ATF5
immunostaining. In comparison with the control short hairpin siRNA-luciferase construct, the short hairpin ATF5 siRNA construct significantly elevated death in cultures of C6 rat glioma cells ( Figure 4b ). As in the case of cultures transfected with d/n ATF5, the cultures transfected with ATF5 siRNA constructs contained large amounts of floating debris, presumably derived from dead cells. Death of cultured glioma cells caused by loss of ATF5 function or expression appeared to be independent of p53. Although U87 and C6 cells express wild-type p53, lines U138, U251, U273 and T98 all have mutated, nonfunctional p53 genes (Asai et al., 1994; Yamagishi et al., 1995; Badie et al., 1999; Vogelbaum et al., 1999) . In addition, cotransfection with d/n p53 failed to rescue C6 cells from the apoptotic effects of d/n ATF5 (data not shown).
We next tested the ATF5 d/n and siRNA constructs for their capacity to trigger death of cultured astrocytes. In contrast with the cultured glioma cells, interfering with ATF5 function or expression had no significant effect on survival of either first passage rat astrocytes (data not shown) or on rat astrocytes that had undergone five passages ( Figure 4 ). As noted above, a majority of the latter cells express ATF5 (Figure 2 ). In addition, two cell lines that express ATF5, HEK293 cells (Aiello et al., 1979) and CAD cells (Qi et al., 1997) , showed no excess cell death when transfected with d/n ATF5 (data not shown). PC12 pheochromocytoma cells and embryonic neural progenitor cells also express high levels of ATF5 and their capacity to differentiate is accelerated by ATF5 d/n and siRNA constructs (Angelastro et al., 2003) . However, in neither case did we observe promotion of death (data not shown). Taken together, these findings indicate that interfering with ATF5 function or expression causes death of cultured glioma cells but not of non-neoplastic astrocytes, or of several additional ATF5 þ cell types. ATF5 loss-of-function triggers exit from cell cycle by astrocytes, but not by C6 glioma cells d/n ATF5 accelerates the differentiation of neural progenitor cells into neurons, astrocytes and oligodendrocytes and, as shown by sharp reduction in BrdU incorporation, promotes their exit from the cell cycle (Angelastro et al., 2003 Mason et al., 2005) . To assess the effect of ATF5 constructs on the growth of cycling high-passage mature astrocytes in vitro, these cells were infected with retroviruses encoding eGFP control, ATF5/eGFP or eGFPAzip, and 4 days later the infected cells were incubated with BrdU for 24 h and then fixed and immunostained for GFP and incorporated BrdU. Like neural progenitor cells, astrocytes expressing exogenous ATF5 showed more than double the incorporation of BrdU. However, such cells expressing d/n ATF5 showed a 10-fold reduction of BrdU incorporation relative to the control (Figure 3n ). By contrast, C6 glioma cells transfected with d/n ATF5 did not exit the cycle and showed slightly more BrdU incorporation than the eGFP-transfected control cells ( Figure 3o ). d/n ATF5 caused the anticipated death in these cultures, indicating that the lack of effect on BrdU incorporation was not due to inactivity of the construct. Thus, d/n ATF5 promotes cell cycle exit of proliferating astrocytes, but not of glioma cells. It has been reported that, in at least some cell types, ATF5 is expressed during G1/S and falls to undetectable levels in G2/M (Persengiev et al., 2002) . However, when we immunostained C6 cells for expression of ATF5 immediately after 4 h of exposure to BrdU, we found many cells that coexpressed ATF5 and incorporated BrdU (Figure 3i-l) . This finding is consistent with the observation that nearly all cells in our glioblastoma cultures express ATF5 (Figures 2 and 3j, k) , even though a substantial proportion are in a replicative state at any one time. Such findings indicate that, at least in GBM cell lines, ATF5 is expressed outside of G1/S. Moreover, when we examined human GBMs, we saw many cases in which cells were in metaphase and also expressed ATF5. An example is given in the inset of Figure 1a .
ATF5 loss-of-function promotes selective death of GBM cells in vivo Although our in vitro experiments revealed that ATF5 loss-of-function promotes selective death of GBM cells, but not of activated astrocytes, it was conceivable that this would not occur in the environment of the brain. Therefore, to extend our in vitro findings to an in vivo model and to further examine the specificity of the death evoked by ATF5 loss-of-function, we infected cells in rat gliomas with a retrovirus expressing d/n ATF5. Tumors were created by stereotactic injection of C6 cells into the striatum of adult rats (1 Â 10 4 cells in 5 ml). After 10 days, retroviruses encoding eGFP or eGFP-NTAzip-ATF5 (1.25 Â 10 4 CFU in 5 ml) were stereotactically introduced into the tumors. Under these conditions, the tumors were large enough to inject, but had not formed large areas of internal necrosis that might interfere with detection of induced cell death. On day 13, the animals were killed and the brains were analysed by immunohistochemistry for retroviral infection (presence of eGFP) and for cell death (TUNEL staining) in the tumor and surrounding tissue.
For both control and d/n ATF5 retroviral infections, staining for eGFP revealed that approximately 0.1-1% of the cells in the tumors were infected. This is consistent with the amount of virus that was injected. For many of the animals, infected cells were detected not only within the tumors but also in cells clearly outside the tumor margins. Although one cannot rule out with certainty that none of the infected cells outside the tumors were infiltrating tumor cells, it appears more likely that these were mainly generated from reactive astrocytes, or other endogenous proliferating cells that were infected by the viruses. When injected into adult rat brains, C6 cells form a well-circumscribed tumor with little infiltration. Moreover, the few cells in C6 tumors that do infiltrate do so along blood vessels (Canoll et al., unpublished data) and we did not observe that infected cells outside the tumors were associated with the vasculature. Rather, the cells were mostly distributed throughout the corpus callosum and had a distribution and morphology most consistent with reactive astrocytes. For these reasons, infected cells that were within and outside of the tumors were separately scored for TUNEL staining.
In the case of animals receiving the control virus, less than 1% (2/252) of the infected cells within the tumors were TUNEL þ . Likewise, there were no TUNEL þ infected cells outside these tumors (0/194). In contrast, 96% (215/225) of the cells infected with the d/n ATF5-expressing virus and that were within the tumors were TUNEL þ (Figures 5 and 6) . Inspection of the nuclei of such cells revealed that many were pyknotic or in various states of degeneration. By comparison, only 2% (1/63) of the infected cells outside the tumors were positive for TUNEL staining (Figures 5 and 6) . Thus, interference with ATF5 function causes death of glioma cells in vivo, but spares cells outside the tumors.
Discussion
Our studies revealed that ATF5 was expressed by all 29 human GBMs we surveyed, as well as by both rat and human glioma cell lines. Although ATF5 expression thus presently appears to be universal among glioblastomas, not all cells in the tumors were positive for ATF5 staining. We do not presently know if this is due to a degree of heterogeneity for ATF5 expression within the tumors or if this is caused by our inability to retrieve all ATF5 antigenic sites in fixed surgically resected tissue. Previous studies have found that in some cell types ATF5 expression is largely limited to the G1/S phases of the cell cycle (Pati et al., 1999; Persengiev et al., 2002) . However, we found high levels of ATF5 staining localized to the condensed chromatin of mitotic cells in human glioblastoma specimens (Figure 1a) . Also, our findings that nearly all cells in cultures of glioblastoma cells are positive for ATF5 expression indicates that, at least in this cell type, ATF5 may be present during other cell cycle phases.
Our previous studies have shown that ATF5 is not expressed in the mature neurons, astrocytes or oligodendrocytes in rodent brain (Angelastro et al., 2003 Mason et al., 2005) . On the other hand, ATF5 is highly expressed by brain neural progenitor/stem cells (Angelastro et al., 2003) , as well as by reactive astrocytes in culture. When constitutively expressed in neural progenitor cells, ATF5 blocks their differentiation into neurons and astrocytes and maintains them in a proliferative state, even in the presence of differentiation-promoting growth factors, such as NGF, NT3 and CNTF (Angelastro et al., 2003 . This raises the possibility that ATF5 contributes to the relatively undifferentiated state of GBMs and to their capacity for uncontrolled growth. However, ATF5 expression alone does not appear to be sufficient for neoplastic transformation. When ATF5 was constitutively expressed in SVZ progenitors in vivo, these cells formed a noninvasive multi-layered hyperplastic mass by 3 1 2 months post-infection that exhibited the morphologic 4 C6 glioma cells into the striatum. After 10 days, retroviruses (1.25 Â 10 4 in 5 ml) expressing eGFP (control) or eGFP-NTAzip-ATF5 were stereotactically injected into the C6 tumors. At 3 days after the injection of retrovirus and a total of 13 days after the injection of C6 cells, the brains were removed, fixed, sectioned and stained for TUNEL (b, f, j, n) and then immunostained with rabbit-anti-eGFP antibodies (a, e, i, m) and stained with Hoechst nuclear dye 33342 (C,G,K,O). (a-h) Cells in a tumor infected with control virus and found outside (a-d) or within (e-h) the tumor. (i-p) Cells in a tumor infected with virus expressing eGFP-NTAzip-ATF5 found outside (i-l) or within (m-p) the tumor. Scale bar is 10 mm. (l1) and (p1) show enlargements of the areas within the boxes indicated in (l, p), respectively. Note: As shown by arrows, the presence of yellow cells (positive for both TUNEL and eGFP) in the merged images only in the case of cells within tumors infected with virus expressing eGFP-NTAzip-ATF5. Scale bar is 100 mm. features of neural progenitors, but not of glioblastoma cells .
A somewhat unanticipated finding here was that ATF5 loss-of-function induced death of glioma cells both in culture and in vivo. This effect was independent of the delivery method employed in that both transient transfection and retroviral infection using the same d/n ATF5 construct produced similar results. Moreover, death was also induced by an ATF5 siRNA transfected either as an oligoduplex or hairpin loop. Significantly, these destructive actions appeared to be selective for glioma cells. The d/n ATF5 had no effect on survival of ATF5-expressing astrocytes in culture or of retrovirally infected (and therefore proliferating) cells in brain that were found outside the margins of experimental tumors. There were also no apoptotic effects on cultured CAD neuroblast cells or human embryonic kidney 293 cells, both of which express detectable ATF5. We have also noted that ATF5 loss-of-function does not compromise survival of ATF5-positive PC12 rat pheochromocytoma cells (Angelastro et al., 2003) , of brain neural progenitor/stem cells either in culture (Angelastro et al., 2003) or in vivo , or of proliferating O4 þ oligodendroglial progenitor cells in vitro or in developing brain .
The mechanisms by which loss of ATF5 function or expression lead to death of glioma cells remain to be fully explored. Both the presence of condensed nuclei in the dying cells and the suppression of death by BAF indicate an apoptotic process. A p53-dependent mechanism appears to be ruled out in that a number of susceptible glioma lines we used are deficient in p53 expression or activity and because we were unable to protect one line with normal p53 function from d/n-ATF5-promoted death by cotransfection with d/n p53. Moreover, over 70% of human GBMs are reported to be deficient in p53 expression, either due to direct mutations of this gene or of others that regulate p53 expression (Collins, 2004) .
Impaired cell cycle control appears to be another major feature of glioblastomas (Collins, 2004) and it is in this context that ATF5 and ATF5 loss-of-function may act. As noted, ATF5 appears to play a role in regulating neural progenitor cell proliferation; constitutive expression of ATF5 maintains such cells in the cycle (even in presence of growth factors that would otherwise promote cell cycle exit), while ATF5 loss-of-function causes such cells to leave the cycle (Angelastro et al., 2003 . One possibility is that ATF5 facilitates passage through critical checkpoints during the cell cycle. In cells such as neural progenitors, loss of ATF5 expression or function may lead to withdrawal from the cycle, whereas in glioblastomas, with abnormal cell cycle control, even with ATF5 loss-of-function, the cells may attempt to continue cycling and pass through checkpoints. This is supported by our data showing that at least one glioma cell line continues to remain in cycle when expressing d/n ATF5. Such inappropriate passage through checkpoints could, in turn, lead to 'mitotic catastrophe' and the triggering of cell death pathways (Canman, 2001; Castedo et al., 2004) . Of potential relevance, inhibition of chk1, a kinase involved in enforcing the G2/M checkpoint, potentiated the capacity of the chemotherapeutic methylating agent temozolomide to promote mitotic catastrophe and death of cultured glioblastoma cell Sonoda et al., 2001 ).
Yet another potential mechanism to account for our findings is that ATF5 acts as a survival factor and that interference with its function or expression therefore triggers death. Persengiev et al. (2002) reported that ATF5 levels fall in several cell lines undergoing death evoked by trophic factor deprivation and that such death was suppressed by constitutive ATF5 expression. These authors also found that a d/n ATF5 lacking a transcriptional regulatory domain promoted death of HeLa and FL5.12 cells in the presence of trophic support. It was further observed that constitutive expression of ATF5 does not affect FL5.12 cell proliferation, and on this basis it was concluded that the activity of ATF5 is purely antiapoptotic (Persengiev et al., 2002) . Although our findings indicate that ATF5 can affect cell proliferation and differentiation and that its loss or absence (as in the case of mature neurons and glia) does not necessarily result in cell death, it remains possible that ATF5 acts as a survival factor for glioma cells independently from its role in cell growth.
In summary, our findings indicate that ATF5 is universally expressed by glioma cells and that interference with its function or expression leads to their death, both in vitro and in vivo. In contrast, ATF5 is undetectable in mature neurons and glia and abrogation of its expression or function does not cause death of brain cells that express this protein, including developing neural progenitor cells or activated astrocytes. These observations raise ATF5 as a potential therapeutic target for treatment of glioblastomas, either by direct intervention in its expression or activity such as achieved here, or by indirectly manipulating other molecules involved in its regulation or function. In either case, the challenge will be to develop suitable reagents that can be delivered to glioblastoma cells with high efficiency.
Materials and methods
Reagents
Cell culture medium DMEM, molecular biology reagents and LipofectAMINE 2000 were from Invitrogen, Inc. Fetal bovine serum was purchased from JRH Biosciences. Mouse monoclonal anti-GFP IgG 1 and anti-BrdU were from Sigma. Goat anti-mouse Alexa 488, Alexa 568, goat anti-mouse IgG 2a Alexa 488, goat anti-mouse IgG 1 Alexa 568, goat anti-rabbit Alexa 488 and 568, and mouse IgG 2a anti-GFP antibody were from Molecular Probes. Rabbit anti-GFP antibody was from BD Biosciences (Clontech). Rabbit anti-Ki67 was from Novacastra. Normal 10% goat serum was from Zymed. Polyclonal rabbit anti-ATF5 was as described previously (Angelastro et al., 2003) .
Immunostaining of human glioblastomas
Paraffin sections (10 mm) of surgically excised GBM tumors (WHO, Grade IV) were provided by the Department of Pathology, Columbia University. Paraffin was removed by heating the sections at 601C for 1-2 h, followed by three incubations in 100% xylene for 5 min each. Subsequent incubations were in 100, 95, 75, 50 and 0% ethanol for 5 min each. The sections were then subjected to antigen retrieval by incubation in 10 mM citrate buffer (pH ¼ 6.0) at 1001C in a Black & Decker HS 800 steamer for 40 min. Endogenous peroxidase was blocked by incubation with 0.3% hydrogen peroxide for 10 min, followed by three washes in water. The tissue was then permeabilized by incubation with 0.04% Tween 20 in TBS (3 Â for 5 min each) and immunostained with ATF5 antiserum (1:600) in PBS containing 1% BSA for 1 h at room temperature. Visualization was achieved with DAB reagent following the manufacturer's protocol (DAKO, Envision System kit). The sections were counterstained with light hematoxylin to reveal nuclei and cellular morphology. Antiserum against the Ki67 antigen (1:1000) was used as a positive immunostaining control.
